<div class="ck-content"><p><strong>Prague, 1 December, 2025</strong>. &nbsp;Zentiva, a leading European manufacturer of affordable, high-quality medicines, today announced the first EU-wide launch of a monoclonal antibody biosimilar, following approval by the European Medicines Agency (EMA). This milestone marks Zentiva’s entry into the biosimilar segment, further strengthening its position as a trusted healthcare partner dedicated to improving patient access to essential treatments.</p></div> <div class="ck-content"><p>The new biosimilar is a monoclonal antibody used in the treatment bone conditions. &nbsp;Zentiva’s biosimilar has been authorised through the EMA’s centralised procedure and will be made available progressively across European markets starting in December.</p><p>Zentiva’s entry into biosimilars forms part of its broader strategic growth plan to diversify the company’s product offering beyond traditional generics. With biologic medicines representing a growing share of healthcare spending in Europe, biosimilars are key to ensuring healthcare system sustainability and patient access to modern therapies.</p></div> <div class="ck-content"><p><strong>Media contacts:</strong></p></div>

Zentiva Expands into Biologics with the EU-Wide Launch of Its First Biosimilar

2025-12-01-zentiva-expands-into-biologics

<div class="ck-content"><p><strong>Prague, Czech Republic; 28 November 2025.</strong> Zentiva, a leading European generics pharmaceutical company, has received the esteemed ESG Transparency Award 2025 by the EUPD Group. This award recognises companies that excel in clarity, structure and transparency in their Environmental, Social and Governance (ESG) reporting.</p><p>The awards were presented at the ESG Summit 2025, as part of the European Sustainability Week 2025, hosted by the EUPD Group. The recognition is a testament to the efforts of industry leaders who have embedded sustainability in their business strategy and communicate it transparently according to relevant standards.</p><p>Zentiva received recognition at the Excellence Level of the ESG Transparency Award 2025 for its high degree of clarity, accessibility and transparency in sustainability reporting. The Excellence Level distinction places Zentiva among the top organisations in Europe in terms of transparent reporting of its ESG disclosures.</p><p>The company excelled in the presentation of a well-structured and strategically grounded sustainability approach that incorporates current European requirements into governance and reporting processes. Furthermore, the disclosure of climate related information, including the use of renewable electricity at European production sites and its integration into a broader long term climate strategy reached a high level of transparency. In addition, Zentiva offered a full calculation of the indirect carbon footprint with externally reviewed methodology to strengthen data integrity and clearly explained its governance structures, highlighting the role of the Audit Committee in approving sustainability related plans. These results underline the determination of Zentiva to strive to drive positive change for society and the environment.</p><p><strong>Steffen Klink, COO of the EUPD Group commented:</strong> <i>“We proudly congratulate Zentiva on its exceptional commitment to transparent ESG communication, clearly demonstrating accountability by publicly detailing material impacts, risks, and opportunities across key environmental, social, and governance areas. This dedication to holistic performance, including ambitious decarbonization targets and robust global policies on ethical conduct and responsible sourcing, sets a definitive benchmark for industry excellence.”</i></p></div> <div class="ck-content"><p><strong>Media contacts:</strong></p></div>

Demonstrating accountability: Zentiva receives prestigious ESG Transparency Award 2025

2025-11-28-demonstrating-accountability

<div class="ck-content"><p>Pink October is a movement powered by our people. From Prague to Paris, Budapest to Bucharest, and beyond, teams embraced Pink October with creativity and heart. Colleagues proudly dressed in pink, transforming offices into vibrant reminders of solidarity. &nbsp;</p><p>Driven by our purpose to provide health and wellbeing for all generations, we began with our own people – organizing sessions and activities across Zentiva that put awareness into action. &nbsp;Local initiatives ranged from educational workshops and health talks to community partnerships, each one showing that prevention starts with awareness, and awareness starts with us. ️ &nbsp;</p><p>We are proud of our employees’ commitment and energy, and we continue to support them with resources and activities that foster health, wellbeing and awareness.</p><p>Zentiva supports breast cancer patients across Europe by providing essential medicines that address all stages of the disease. We fight the battle against cancer by expanding our portfolio, thereby broadening access to high-quality, affordable cancer treatment.&nbsp;</p></div>

Zentiva stands with Breast Cancer Awareness Month

2025-10-30-pink-october

Pink October

zentiva

daily

Header

Footer

Default

News

2024-10-16-investment-agreement-apontis-pharma

Zentiva signed an investment agreement and will launch a voluntary public purchase offer for Apontis Pharma

Latest news

Zentiva Expands into Biologics with the EU-Wide Launch of Its First Biosimilar

Demonstrating accountability: Zentiva receives prestigious ESG Transparency Award 2025

Zentiva stands with Breast Cancer Awareness Month

Explore

Stay tuned

Get in touch